Skip to main content
AHCO
NASDAQ Industrial Applications And Services

AdaptHealth Swings to a $133.9M Q2 Loss on a $144.2M Goodwill Impairment, Cuts Guidance, and Launches Restructuring

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$6.73
Mkt Cap
$912.923M
52W Low
$6.14
52W High
$13.43
52W Position info
9.6% above low
Off High info
50% below high
Rel. Volume info
11× avg
Market data snapshot near publication time

AHCO is trading near its 52-week low of $6.14 (9.6% above the low) on elevated volume (11× avg).

Summary

AdaptHealth reported a $133.9M Q2 net loss after a $144.2M goodwill impairment, cut FY2026 guidance, and announced a restructuring plan. The company is selling its Diabetes Health business for $235M and disclosed a material cybersecurity incident.


Key Events · Earnings and Guidance · AHCO

  • Q2 Net Loss of $133.9M

    Net loss attributable to AdaptHealth Corp. was $133.9M, or $0.99 per share, compared to net income of $14.7M a year ago. The loss was driven by a $144.2M non-cash goodwill impairment charge in the Respiratory Health and Wellness at Home segments.

  • $144.2M Goodwill Impairment

    A quantitative impairment test triggered by the planned divestiture of the Diabetes Health business and revised financial projections resulted in a $144.2M non-cash charge, wiping out goodwill in two reporting units.

  • FY2026 Guidance Cut

    The company reduced its full-year Adjusted EBITDA guidance by $6M (implied by the prior 8-K on August 4, 2026), reflecting weaker operating performance and higher costs.

  • Restructuring Plan Announced

    A cost-savings plan including headcount reductions and a business wind-down is expected to generate $26.8M in annual savings, with total costs of approximately $7.0M. $6.1M in charges were recognized in Q2.


Analysis · AHCO · Industrial Applications And Services

A massive non-cash goodwill impairment in the Respiratory Health and Wellness at Home segments drove AdaptHealth to a deep Q2 loss, reflecting deteriorating fair values. The company also cut full-year Adjusted EBITDA guidance, launched a restructuring plan expected to save $26.8M annually, and is selling its Diabetes Health business for $235M to pay down debt. Adding legal overhang, a material cybersecurity breach and multiple government investigations were disclosed. The quarter marks a sharp deterioration in profitability and a strategic pivot to stabilize the balance sheet.

At the time of this filing, AHCO was trading at $6.73 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $912.9M. The 52-week trading range was $6.14 to $13.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AHCO - Latest Insights

AHCO
Aug 04, 2026, 7:58 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $7.90
Real-time Price: $6.73 info
Change: -$1.17 (-15%) info
Market Cap: $912.923M info
AHCO
Aug 04, 2026, 7:09 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $8.60
Real-time Price: $6.73 info
Change: -$1.87 (-22%) info
Market Cap: $912.923M info
AHCO
Jul 20, 2026, 4:37 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $11.17
Real-time Price: $6.73 info
Change: -$4.44 (-40%) info
Market Cap: $912.923M info
AHCO
Jul 20, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.17
Real-time Price: $6.73 info
Change: -$4.44 (-40%) info
Market Cap: $912.923M info
AHCO
Jul 07, 2026, 4:45 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $10.15
Real-time Price: $6.73 info
Change: -$3.42 (-34%) info
Market Cap: $912.923M info